A Study to Examine the Human Papillomavirus Types Exposure in Women From Southern Africa and Brasil
This is a study to determine what Human Papillomavirus HIV seropositive women in Botswana, South Africa and Brasil have been exposed to during their life. The Human Papillomavirus causes cervical cancer. Different types are more likely to lead to cancer than other types. A vaccine has been made to fight infection against HPV 16 and 18 which has been shown to cause cervical cancer in America and Europe. What HPV type cause cancer in other countries is not as well studied.
Hypothesis HPV serology will demonstrate that exposure to each HPV type in Gardisil (6,11,16,18) will be <50% in HIV seropositive women in resource limited countries.
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||A Pilot Observational Study to Determine the Prevalence of HPV Serology in HIV Seropositive Women From Subsaharan Africa and Brasil|
- To determine the seroprevalence of HPV types 6,11,16,18 in HIV serOpositive women for Botswana, South Africa and Brazil [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Biospecimen Retention: None Retained
Blood /plasma specimen 10cc
|Study Start Date:||February 2009|
|Study Completion Date:||December 2010|
|Primary Completion Date:||March 2010 (Final data collection date for primary outcome measure)|
HIV seropositive women from an HIV Antiretroviral therapy clinic in Johannesburg South Africa
A cohort of HIV seropositive women from Gabarone Botswana
A cohort of HIV seropositive women from Rio De Janeiro Brasil
Plasma from HIV seropositive women will be taken and sent to MERCK in the USA to evaluate what the antibody titers of HPV 6,11,16 and 18. .
|Fundacao Oswaldo Cruz|
|Rio De Janeiro, Brazil|
|University of Witwatersrand/Helen Joseph Hospital|
|Johannesburg, South Africa|
|Principal Investigator:||Cynthia S Firnhaber, MD||Clinical HIV Research Unit University of Witwatersrand|